Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label, 2-stage study of INCB047986 administered orally to subjects with primary myelodysplastic syndrome (MDS) refractory to or unlikely to respond to erythropoiesis-stimulating agents (ESAs)

Next Previous
Search
Trial Profile

A randomized, open-label, 2-stage study of INCB047986 administered orally to subjects with primary myelodysplastic syndrome (MDS) refractory to or unlikely to respond to erythropoiesis-stimulating agents (ESAs)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INCB 47986 (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Incyte Corporation

    • Most Recent Events

    • 22 Feb 2015 Status changed from active, no longer recruiting to discontinued due to business decision, as per ClinicalTrials.gov record.
    • 02 Sep 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
    • 03 Jun 2014 New source identified and integrated (Oregon Health and Science University).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top